Read Our Latest Research Report on IGMS IGM Biosciences Trading Down 3.3 % IGMS stock opened at $1.77 on Monday. The firm’s 50-day moving average is $7.65 and its two-hundred day moving average ...

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are ...

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 69% phase ...

IGM Financial Inc. (TSE:IGM – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat reports.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late ...

UBS analyst Jo Walton maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €115.00. The company’s shares ...